Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)

Drake, Marcus; MacDiarmid, Scott; Chapple, Christopher; ESEN, AHMET; Athanasiou, Stavros; Cambronero Santos, Javier; Mitcheson, David; Herschorn, Sender; Siddiqui, Emad; Huang, Moses; Stoelzel, Matthias

doi:10.1111/ijcp.12944

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)

Drake M. J., MacDiarmid S., Chapple C. R., ESEN A. A., Athanasiou S., Cambronero Santos J., ...Daha Fazla

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, cilt.71, sa.5, 2017 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 71 Sayı: 5
Basım Tarihi: 2017
Doi Numarası: 10.1111/ijcp.12944
Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aims/objectives: In the BESIDE study, combination therapy (antimuscarinic [solifenacin] and beta(3)-adrenoceptor agonist [mirabegron]) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder (OAB) patients; however, a potential synergistic effect on the cardiovascular (CV) system requires investigation.